Key Takeaways
- A paper published on August 29, 2026 identified 1,247 records, assessed 146 full texts, and retained 64 records about GHK or GHK-Cu.
- The headline count is not 64 clinical trials: 24 retained records were reviews, and much of the remaining literature used cell, excised-tissue, or animal models.
- The authors call their work a structured narrative review with PRISMA-aligned methods because its protocol was not prospectively registered. It is not a meta-analysis.
- A 2015 primary study showed that polymeric microneedle pretreatment increased GHK-Cu transport in laboratory skin models, but it was not a human treatment trial.
- CuHeal, NCT07437586, is a recruiting Phase 2 split-wound study with estimated enrollment of 60 healthy adults. No results are posted.
- FDA currently separates non-injectable GHK-Cu under evaluation from injectable-route GHK-Cu, for which it identifies safety concerns. This is a compounding-policy status, not approval.
GHK-Cu has an extensive research literature, but its evidence is not evenly distributed. The new 2026 review maps many laboratory and secondary records while finding a much thinner human evidence layer. The most accurate conclusion is not that GHK-Cu is “proven,” but that biological plausibility, delivery research, and an active trial pipeline now need stronger completed human studies.
Research boundary: This article is for research education only. It is not medical advice and contains no dosing, preparation, route, administration, treatment, efficacy, or safety guidance. BioPharma materials are for laboratory research only and are not intended for human or veterinary use.
What Is GHK-Cu?
GHK is the tripeptide glycyl-L-histidyl-L-lysine. GHK-Cu is its copper(II)-bound complex, also called copper tripeptide-1 in some cosmetic literature. The distinction matters because experiments may test unbound GHK, GHK-Cu, a formulated gel, a carrier system, or a combination product. Those materials should not be treated as interchangeable.
GHK-Cu appears in research on extracellular-matrix biology, cell signaling, tissue models, wound models, skin delivery, and cosmetic formulations. BioPharma’s GHK-Cu beginner’s guide covers its identity and general research context. This update asks a narrower question: how strong is each evidence tier in 2026?
How the New 2026 Review Mapped the Literature
The August 29 paper in Archives of Internal Medicine Research searched PubMed, ScienceDirect, and CENTRAL and also used citation chasing. It reports 1,247 identified records, 891 after duplicate removal, 160 sought for retrieval, 146 assessed as full text, and 64 retained after 82 full-text exclusions. Its stated publication window was January 1, 2005 through May 1, 2026.
Why “PRISMA-aligned” needs a qualifier
The paper’s title calls it a systematic review, but its methods section says the protocol was not registered in PROSPERO. The authors therefore characterize it as a structured narrative review with PRISMA-aligned methodology. It also performs a qualitative synthesis rather than a meta-analysis: no pooled GHK-Cu effect estimate is reported. That distinction limits how confidently readers can compare outcomes across dissimilar studies.
Why 64 records do not mean 64 independent experiments
The review says 24 of the 64 records—37.5%—were reviews. Its eligibility rules allowed primary studies, systematic reviews, and narrative reviews, so overlap is possible when secondary papers discuss the same foundational experiments. The retained-record total is useful for mapping a literature, but it should not be read as a trial count or multiplied evidence strength.
GHK-Cu Evidence Tiers: What Each Level Can Support
| Evidence tier | Representative source | What it can support | What it cannot establish |
|---|---|---|---|
| Cell culture | PMID 11045606 | GHK-Cu-associated changes in MMP-2, TIMP-1, and TIMP-2 measurements in cultured dermal fibroblasts | A clinical outcome, whole-organism safety, or benefit in people |
| Animal wound model | PMID 8227353 | Changes in matrix-related measurements in rat wound chambers under the tested conditions | Effect size or safety in a human wound population |
| Laboratory delivery models | PMID 25690343 | Microneedle-associated transport through excised skin models and model-specific tolerability observations | A human treatment result or a universal delivery protocol |
| Secondary synthesis | 2026 review, DOI 10.26502/aimr.0255 | Literature mapping, study-model classification, and gap identification | A pooled effect estimate or replacement for appraisal of each primary study |
| Recruiting human trial | NCT07437586 | Planned design, population, outcomes, sponsor, and current registry status | Results, efficacy, completed enrollment, or a safety conclusion |
What the Primary Mechanism Studies Actually Measured
Fibroblast matrix-remodeling signals
In a cultured-fibroblast experiment, GHK-Cu increased MMP-2 in conditioned media and increased MMP-2 messenger RNA. The researchers also reported increased secretion of TIMP-1 and TIMP-2. These findings concern matrix-remodeling measurements in an isolated cell system. They are mechanistic evidence, not proof of tissue repair or a human outcome.
Rat wound-chamber observations
A 1993 study used wire-mesh wound chambers implanted in rats. Under that model, GHK-Cu exposure was associated with concentration-dependent changes in dry weight, DNA, total protein, collagen, glycosaminoglycans, and collagen messenger RNA. Species, model, exposure conditions, and laboratory endpoints limit direct translation to humans.
This separation is essential: a coherent mechanism can justify the next experiment, but it cannot substitute for a controlled clinical result.
Microneedle Delivery: Strong Transport Signal, Limited Outcome Evidence
The review gives special attention to microneedles because GHK-Cu is hydrophilic and intact skin presents a delivery barrier. In the 2015 Pharmaceutical Research study, polymeric microneedle pretreatment increased transport in laboratory skin models. Over nine hours, the researchers measured 134 ± 12 nanomoles of peptide and 705 ± 84 nanomoles of copper through microneedle-treated human skin, while they reported almost no transport through intact human skin.
What that experiment did—and did not—test
The study used in vitro skin models, cell assays, and porcine assessments. It measured penetration and model-specific irritation observations; it did not randomize people to a GHK-Cu treatment and measure healing, appearance, or another clinical endpoint. The paper supports a delivery mechanism under its tested conditions, not a consumer procedure or human-use protocol.
Registered Human Research: The CuHeal Trial
NCT07437586, known as CuHeal, is listed as recruiting. The registry describes a randomized, double-blind, vehicle-controlled, split-wound Phase 2 study with estimated enrollment of 60 healthy adults. Two standardized wounds within each participant receive randomized assignments, and the primary outcome is time to complete re-epithelialization within 21 days.
The registry reports no results. Estimated enrollment is a target, not a completed count, and registration describes a planned experiment rather than its outcome. BioPharma’s dedicated CuHeal trial guide explains the paired design and endpoints without repeating them here.
Regulatory Status: Category Is Not Approval
FDA’s current 503A category document lists GHK-Cu except for injectable routes in Category 1, meaning it is under evaluation within that compounding-policy framework. FDA separately lists GHK-Cu for injectable routes among substances that may present significant safety risks, citing possible immunogenicity from aggregation and peptide-related impurities and limited human safety data.
These are route-specific compounding-policy classifications. They do not establish an FDA-approved indication, clinical effectiveness, or equivalence between a catalog research material and any formulation studied in a paper or registry.
What Is Not Yet Known
- Whether the CuHeal primary endpoint will be met, because the trial is recruiting and has no posted results.
- Whether findings from excised skin, cultured cells, or animal wounds will reproduce as meaningful human outcomes.
- How results vary by exact GHK-Cu identity, formulation, carrier, purity profile, tissue model, and endpoint.
- Whether commonly cited cosmetic studies have adequate randomization, concealment, masking, validated outcomes, and complete peer-reviewed reporting.
- Whether positive findings replicate across independent research groups rather than extending the same source literature.
- What large, completed, adequately powered human studies show for many claims promoted online.
How to Read the Next GHK-Cu Study
| Question | Why it matters |
|---|---|
| What exact material and formulation were tested? | GHK, GHK-Cu, gels, carriers, and combination products are not interchangeable. |
| Was the evidence cellular, animal, excised tissue, or human? | Each model supports a different level of inference. |
| Was the protocol registered before results were known? | Prospective registration helps readers detect outcome switching. |
| Were randomization, allocation concealment, and masking described? | Weak reporting can hide important bias. |
| Were effect sizes and uncertainty intervals reported? | A p-value alone does not show magnitude or precision. |
| Was the finding independently replicated? | Independent confirmation is stronger than repeated work from one program. |
Key Terms and Definitions
- Evidence tier
- A level of evidence defined by study design and model, not by how persuasive a claim sounds.
- PRISMA
- A reporting framework for systematic reviews that improves transparency; following it does not by itself guarantee low bias.
- Systematic review
- A structured synthesis based on a defined search and eligibility process.
- Meta-analysis
- A statistical pooling of results across sufficiently comparable studies. The 2026 GHK-Cu review did not perform one.
- Microneedle
- A micron-scale structure used experimentally to create pathways across the skin barrier.
- Vehicle-controlled
- A design comparing an active formulation with the same base formulation without the active material.
- Re-epithelialization
- Restoration of epithelial coverage across a wound surface.
Frequently Asked Questions About GHK-Cu Evidence
What is GHK-Cu?
GHK-Cu is a complex of the tripeptide glycyl-L-histidyl-L-lysine and copper(II). Researchers also use the name copper tripeptide-1 in cosmetic contexts.
What did the 2026 GHK-Cu review find?
It retained 64 records from 1,247 identified records and described a large but predominantly preclinical and secondary literature, with limited full-paper human randomized evidence.
Was the 2026 paper a meta-analysis?
No. It did not pool effect sizes. Because its protocol was not prospectively registered, the authors describe it as a structured narrative review with PRISMA-aligned methods.
How many of the 64 records were reviews?
The paper reports that 24 of 64 records, or 37.5%, were narrative or systematic reviews. That means the record count is not a count of independent experiments.
What does in vitro GHK-Cu evidence establish?
It can identify responses in isolated cells, such as changes in matrix-related measurements. It cannot establish a clinical effect, safety profile, or outcome in people.
What did the microneedle delivery study test?
The 2015 study measured GHK-Cu transport after polymeric microneedle pretreatment in laboratory skin models and also used cellular and porcine assessments. It was not a human treatment trial.
Is there a registered human GHK-Cu trial?
Yes. NCT07437586, called CuHeal, is a recruiting Phase 2 split-wound study with estimated enrollment of 60 healthy adults. The registry currently posts no results.
What is a split-wound design?
Two standardized wounds in the same participant receive different randomized assignments. This within-participant comparison can reduce variation between people.
Is GHK-Cu FDA-approved?
No FDA-approved indication is established by the reviewed sources. A compounding-category listing or an advisory review process is not FDA approval.
What is FDA Category 1 versus Category 2 for GHK-Cu?
FDA currently lists non-injectable GHK-Cu in Category 1 under evaluation and identifies injectable-route GHK-Cu in Category 2 because of safety concerns. Neither category is an approval.
What is not yet known about GHK-Cu?
Large completed human trials with clearly reported randomization, masking, validated endpoints, effect estimates, and independent replication remain missing for many promoted claims.
Does this article provide human-use instructions?
No. It is research education only and provides no dosing, preparation, route, administration, treatment, efficacy, or safety instructions.
Sources
- Najafi N, et al. A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu in Topical Microneedle Delivery. Archives of Internal Medicine Research. 2026;9:269–293. DOI 10.26502/aimr.0255. Structured narrative review with PRISMA-aligned methods.
- Microneedle-Mediated Delivery of Copper Peptide Through Skin. Pharmaceutical Research. 2015. PMID 25690343. Primary laboratory delivery study.
- In vivo stimulation of connective tissue accumulation by GHK-Cu in rat experimental wounds. Journal of Clinical Investigation. 1993. PMID 8227353. Primary animal study.
- GHK-Cu stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sciences. 2000. PMID 11045606. Primary cell study.
- ClinicalTrials.gov NCT07437586: CuHeal. Recruiting Phase 2 registry record; no posted results.
- FDA: 503A Categories Update. Current category and process document.
- FDA: Substances in Compounding that May Present Significant Safety Risks. Route-specific GHK-Cu safety statement.
View GHK-Cu Research Materials
Qualified researchers can compare BioPharma’s GHK-Cu 50mg research material and GHK-Cu 100mg research material, or review the BioPharma FAQ. Labeled amounts identify catalog products; they are not doses. Catalog materials are not represented as equivalent to a microneedle study formulation or the CuHeal investigational gel.
Research disclaimer: For research and laboratory use only. Not intended for human or veterinary use. This article does not constitute medical advice. BioPharma provides no dosing, preparation, route, administration, treatment, efficacy, or safety instructions.
